OMT-28

Omeicos Therapeutics GmbH · Phase 2 active Small molecule

At a glance

Generic name	OMT-28
Also known as	17,18-epoxyeicosatetraenoic acid analog
Sponsor	Omeicos Therapeutics GmbH
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION) (PHASE2)
Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF) (PHASE2)
Safety and Pharmacokinetic Study of OMT-28 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OMT-28 CI brief — competitive landscape report
OMT-28 updates RSS · CI watch RSS
Omeicos Therapeutics GmbH portfolio CI